Nurse Practitioner, Gerontology · Las Vegas, NV
NPI
1285364877
Since 2022
Specialty
Nurse Practitioner, Gerontology
Code 363LG0600X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
4475 S Eastern Ave
Las Vegas, NV, 89119
Phone (702) 877-5119
Groups this clinician bills Medicare through
Medicare paid, 2024
$9,554
165 services
Medicare patients, 2024
58
Average age 66
Drug cost, 2024
$2.4M
3,534 prescriptions
Company payments, 2025
$407
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rennette T Bulatao was code 99214 (office e&m - established), 107 times for 53 patients. In total Rennette T Bulatao billed 165 services in 7 codes, and Medicare paid $9,554.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-04-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 107 | 53 | $70.99 | $7,596 |
| 95251 Test - Miscellaneous | Office | 40 | 22 | $21.20 | $848 |
By year: 2023 $6,664 for 90 services; 2024 $9,554 for 165 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rennette T Bulatao prescribed most often to Medicare patients was Lantus Solostar (Insulin Glargine,hum.Rec.Anlog), with 497 prescriptions and refills. In total Rennette T Bulatao wrote 3,534 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 497 | 883 | 193 | $88K |
| Jardiance Empagliflozin | 482 | 1,012 | 155 | $614K |
| Mounjaro Tirzepatide | 241 | 362 | 60 | $401K |
| Humalog Kwikpen U-100 Insulin Lispro | 241 | 420 | 99 | $66K |
| Levothyroxine Sodium Generic | 191 | 491 | 62 | $1,475 |
| Metformin Hcl Generic | 158 | 444 | 65 | $1,322 |
| Ozempic Semaglutide | 147 | 230 | 37 | $220K |
| Insulin Lispro Kwikpen U-100 Insulin Lispro | 140 | 226 | 64 | $34K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 140 | 385 | 74 | $20K |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | 119 | 200 | 38 | $163K |
| Trulicity Dulaglutide | 98 | 175 | 28 | $173K |
| Rybelsus Semaglutide | 90 | 144 | 34 | $137K |
| Ultra-Fine Micro Pen Needle Pen Needle, Diabetic | 76 | 188 | 39 | $13K |
| Glimepiride Generic | 74 | 209 | 36 | $738 |
| Farxiga Dapagliflozin Propanediol | 66 | 150 | 23 | $85K |
Brand drugs: 2,619 claims; generic drugs: 584 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rennette T Bulatao $407 ($407 in general payments such as food, travel and fees) from 3 companies. The largest payer was Beta Bionics, Inc. with $212.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.